After getting the first ever approvals in CAR-T in 2017 for Novartis and Gilead/Kite, you would think that the industry could rest on its laurels. But we’re only at the beginning of the CAR-T journey, and everyone is already thinking about CAR-T 2.0, aimed at making the next wave of drugs safer, more effective, more accessible for patients, while also deepening our understanding of its place within the immune system and the fight against cancer.

Companies are already looking for better ways to tweak the cell therapy technology; at this breakfast, pioneers of the next-gen CAR-T field about the challenges inherent in shaping a new field through clinical research; the new methodologies they are using in their quest; and what lessons we’ve already learned from current CAR-T drugs.

Learn More >